Avid Bioservices — Merger or Acquisition (January 2025)
16 slides from Avid Bioservices's merger presentation, Jan 8, 2025
Slide 1: Avid Bioservices Sale to GHO and Ampersand
Avid Bioservices Sale to GHO and Ampersand Delivering Stockholders Significant, Immediate and Certain Cash Value January 2025
Slide 2: GHO and Ampersand Transaction: The Value-Maximizing Alternative for Avid Stockholders
2 GHO and Ampersand Transaction: The Value- Maximizing Alternative for Avid Stockholders The Avid Board of Directors recommends Avid Stockholders vote FOR the transaction today Provides significant, immediate and certain cash value to Avid stockholders Reflects a robust process conducted by the Boar
Slide 3: Compelling Valuation at a Significant Premium
3 Compelling Valuation at a Significant Premium Selected publicly traded comparable companies include Bachem, Catalent, Lonza, Oxford Biomedica and PolyPeptide Based on Avid Management’s Probability-Adjusted 5-Year Plan (as of July 15, 2024); associated FY 2025E revenue and Adj. EBITDA figures are $
Slide 4: Premium Adjusted EBITDA Multiple Achieved Compared to Selected Publicly Traded CDMOs
4 3 4 Premium Adjusted EBITDA Multiple Achieved Compared to Selected Publicly Traded CDMOs Source: Capital IQ as of 11/05/2024; public filings; equity research Note: Figures annualized in accordance with Avid’s fiscal year reporting period of April 30. Convertible notes are in the money and are repr
Slide 5: Significant Premium to Stock Price Despite Recent Volatility
5 mpersan ransa tion ri e 3 000 6 000 9 000 12 000 15 000 4.00 5.00 6.00 .00 8.00 9.00 10.00 11.00 12.00 13.00 18 000 6 Nov 6 Dec 6 an 6 Feb 6 Mar 6 Apr 6 May 6 un 6 ul 6 Aug 6 ep 6 ct 6 Nov ra in ol me hare ri e Significant Premium to Stock Price Despite Recent Volatility Source: Capital IQ 6/23/24
Slide 6: A Robust, Conflict-Free Process with Thoughtful, Comprehensive Strategic Transaction Process
A Robust, Conflict-Free Process with 24 Parties Thoughtful, Comprehensive Strategic Transaction Process GHO and Ampersand initially approached the Company in early 2024. The Board rejected GHO and Ampersand’s two initial proposals ( une 5 Initial Proposal and une 23 Revised Proposal) before engaging
Slide 7: Competitive Process Resulted in Five Improvements to GHO and Ampersand Transaction Price
une 5 2024 une 23 2024 eptember 5 2024 ctober 1 2024 ctober 21 2024 Final Deal Price Competitive Process Resulted in Five Improvements to GHO and Ampersand Transaction Price GHO / Ampersand Transaction Price: $12.50 19% Increase from Initial Bid $11.50 $12.00 6
Slide 8: Additional Factors Expose Risks to Standalone Plan
Additional Factors Expose Risks to Standalone Plan There are a range of tailwinds and challenges facing the biologics manufacturing industry, that the market had already priced in prior to the sale announcement including: uncertainty around the recovery in biotech funding / BIOSECURE Act; increased
Slide 9: Participants in the Sale Process Recognize Avid's Challenging Operating Environment and Execution Risks
arti ipants in the ale ro ess Re o nize vi ’s Challen in peratin Environment and Execution Risks Key Risks Identified by Sale Process Participants Uncertainty around the availability of biotechnology funding Rising geopolitical tensions and implications on supply chain Industry-wide macroeconomic he
Slide 10: The Transaction De-Risks Avid's Future as a Standalone Company
10 The Transaction De-Risks vi ’s F t re as a tan alone Company Management Forecast: Probability-Adjusted 5-Year Plan FY 19A FY 20A FY 21A FY 22A FY 23A FY 24A FY 25E FY 26E FY 2 E FY 28E FY 29E %YoY Rev. Growth – 11.4% 60.6% 24.8% 24.8% (6.3%) 13.2% 17.6% 19.3% 15.2% 10.5% Adj. EBITDA ($1) ($5) $20
Slide 11: Analysts' Estimates for Avid Have Been Consistently Revised Over Time
11 3 66 99 18 3 3 5 26 58 20 20 2 19 39 2 15 32 80 60 40 20 0 120 100 nalysts’ Estimates for vi ave Been Consistently Re e ver ime, Exposing the Risks and Uncertainty to the Standalone Plan 199 286 38 180 230 292 139 166 216 151 14 148 148 139 164 201 139 164 198 0 100 200 300 400 500 FY 2023A FY 20
Slide 12: Roadmap to Completion
Roadmap to Completion 11/6/2024 12/3/2024 12/18/2024 12/30/2024 1/30/2025 ASAP Thereafter Definitive Proxy filing Execution of the Definitive Agreement Preliminary Proxy Statement filed with the SEC Announced HSR Clearance Anticipated closing date Seek stockholder approval at special meeting 12
Slide 13: Avid Board Recommends that Stockholders Vote to Approve the Transaction
Avid Board Recommends that Stockholders Vote to Approve the Transaction Now is the right time for this transaction given it: Provides significant, immediate and certain cash value to Avid stockholders; Reflects a robust process conducted by the Board to ensure we are maximizing value; and De-risks f
Slide 14: Appendix
Appendix 12
Slide 15: Safe Harbor Statement: Forward Looking Statements
Safe Harbor Statement 12 Forward Looking Statements This communication contains “forward-looking statements” which include but are not limited to all statements that do not relate solely to historical or current facts such as statements regarding the Company’s expectations, intentions or strategies
Slide 16: Safe Harbor Statement: Additional Information and Where to Find It
Safe Harbor Statement 12 Additional Information and Where to Find It The Company has filed a proxy statement with the U. . ecurities and Exchange Commission (“ EC”) with respect to a special meeting of stockholders to be held in connection with the proposed transaction. Promptly after filing the def
Avid Bioservices — Merger or Acquisition (January 2025) on 6ix